List of works - Jesús San Miguel

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

scientific article published in June 2005

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

scientific article

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

scientific article

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

article

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

scientific article published on 2 June 2015

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

scientific article published on 3 August 2015

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

scientific article published on 03 February 2011

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

scientific article

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

scientific article

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

scientific article published on August 2016

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

scientific article

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

scientific article

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

scientific article published on 11 February 2008

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

scientific article published on 09 August 2007

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

scientific article published on 23 August 2010

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

scientific article

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

scientific article published on 03 February 2011

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

scientific article

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

scientific article published on 03 February 2011

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

scientific article published on 18 October 2010

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

scientific article

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

scientific article published on 12 December 2017

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

scientific article published on 02 July 2013

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

scientific article published on 12 August 2011

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

scientific article

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

scientific article published on 29 March 2011

Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling.

scientific article

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

scientific article published on 08 July 2008

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

scientific article published on 13 June 2006

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

scientific article published on 26 June 2009

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

article

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

scientific article published on June 2006

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

scientific article published on 16 August 2005

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

scientific article published on 29 November 2011

Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals

scientific article

1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells

scientific article published on 01 January 1983

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.

scientific article published on 20 January 2017

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

scientific article published on 01 September 2001

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

scientific article published on 19 November 2012

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

scientific article

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting.

scientific article published on 3 November 2009

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

scientific article

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

scientific article published on 14 March 2011

Therapy-related acute promyelocytic leukemia.

scientific article published in June 2003

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

scientific article

Panobinostat for the Treatment of Multiple Myeloma.

scientific article published on 11 September 2015

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

scientific article

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

scientific article published on 28 April 2008

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

scientific article published on December 2008

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

scientific article published on 19 March 2009

List of works by Jesús San Miguel

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling.

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals

1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting.

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

Therapy-related acute promyelocytic leukemia.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

Panobinostat for the Treatment of Multiple Myeloma.

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.